Final phase 2 ARNEO results in high-risk prostate cancer: neoadjuvant degarelix plus apalutamide vs degarelix plus placebo before prostatectomy did not significantly reduce 3-year biochemical recurrence (secondary endpoint; 24% vs 39%, p=0.18); quality of life was similar.
RCT
Giesen et al. Final Results of the Randomised Phase 2 Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer (ARNEO)